News from oncopeptides ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

21 Oct, 2020, 07:42 BST Nomination committee in Oncopeptides established

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the composition of the Nomination Committee for the Annual General Meeting 2021 ...


19 Oct, 2020, 07:54 BST Oncopeptides has submitted an Investigational New Drug application to FDA for the second drug candidate from the PDC platform

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company has submitted an Investigational New Drug (IND) application to the U....


14 Oct, 2020, 17:12 BST Oncopeptides signs € 40 million loan agreement with the EIB

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the company has entered into a loan agreement with the European Investment Bank...


12 Oct, 2020, 07:22 BST With the priority review underway at FDA, Oncopeptides moves forward with intent to file for conditional approval of melflufen with EMA

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company has informed the European Medicines Agency, EMA, about its intention ...


01 Oct, 2020, 07:19 BST Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) announced today that the open-label Expanded Access Program, sEAPort, for eligible U.S. patients, is...


04 Sep, 2020, 07:21 BST Oncopeptides completes the extended enrollment for the pivotal phase 3 OCEAN study in relapsed refractory multiple myeloma - 495 patients included

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the last patient has been successfully enrolled in the pivotal phase 3 study...


29 Aug, 2020, 11:35 BST FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the US Food and Drug Administration, FDA, has granted priority review for...


26 Aug, 2020, 07:30 BST Oncopeptides AB: Interim Report Q2 2020

Summary Financial overview April 1 - June 30, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 401.0 M (loss: 171.9) Loss per...


07 Aug, 2020, 07:20 BST Oncopeptides initiates the first study with melflufen outside multiple myeloma and enrolls the first patient in the phase 1/2 AL amyloidosis study

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) announced today that the first patient has been enrolled in the Immunoglobulin Light Chain (AL)...


04 Aug, 2020, 14:54 BST Oncopeptides starts the phase 2 PORT study comparing peripheral versus central administration of melflufen and dexamethasone in multiple myeloma

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announced that the first patient has been enrolled in the phase 2 PORT study. The study, which...


31 Jul, 2020, 14:43 BST Number of shares and votes in Oncopeptides

Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of shares being...


30 Jun, 2020, 16:58 BST Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO

Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief...


30 Jun, 2020, 13:17 BST Number of Shares and Votes in Oncopeptides

Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of...


30 Jun, 2020, 07:36 BST Oncopeptides Submits a New Drug Application to the FDA for Accelerated Approval of Melflufen in Triple-class Refractory Multiple Myeloma Patients

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company submits a New Drug Application (NDA) to the U.S. Food and Drug...


29 Jun, 2020, 16:53 BST Oncopeptides Strengthens the Pre-clinical Development and Takes over Kancera's Solna-based Laboratory for Drug Development as of July 1

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the Company has agreed with Kancera to take over Kancera's drug development facility in ...


15 Jun, 2020, 07:15 BST Oncopeptides Reports Positive Results From Full Data Set of Phase 2 HORIZON Trial in Triple-class Refractory Multiple Myeloma Patients

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the full top-line results from the pivotal phase 2 HORIZON study, evaluating...


11 Jun, 2020, 08:47 BST Oncopeptides Hosts a Virtual Symposium at the 25th European Hematology Association Congress on Challenges in Managing Patients with Myeloma

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the Company hosts a symposium at the EHA 25 Virtual Edition on June 13th, focusing on...


01 Jun, 2020, 07:25 BST New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that patients in the OCEAN study stay on treatment longer than previously estimated. As a...


29 May, 2020, 10:24 BST Number of shares and votes in Oncopeptides

ncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of shares being...


28 May, 2020, 07:15 BST Oncopeptides Reinitiates Patient Enrollment to the Melflufen Clinical Program Following a Temporary Pause due to the COVID-19 Pandemic

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that the company starts patient enrollment to its clinical program following the temporary...


26 May, 2020, 16:46 BST Bulletin From the Annual General Meeting in Oncopeptides AB (publ)

Oncopeptides AB (publ)'s (ONCO) Annual General Meeting 2020 was held today, at Tändstickspalatset in Stockholm. At the Annual General Meeting, the...


26 May, 2020, 07:32 BST Oncopeptides AB: Interim Report Q1 2020

Financial overview January 1 - March 31, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 297.3 M (loss: 134.1) Loss per share, ...


22 May, 2020, 07:21 BST Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces a successful completion of enrollment in the pivotal phase 3 study OCEAN for the treatment of...


15 May, 2020, 11:28 BST Oncopeptides Presents Pre-clinical Melflufen Data at the AACR Annual Meeting 2020 That Further Validates the Technical Platform, PDC

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that new pre-clinical data evaluating the potential of the lead candidate melflufen...


14 May, 2020, 14:15 BST Oncopeptides Announces New Clinical and Preclinical Melflufen Data at the Upcoming European Hematology Association Meeting

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that data from the pivotal phase 2 study HORIZON, and additional clinical and preclinical...